Roche leaves Abbott in the dust when it comes to US approval times
The Swiss group has succeeded with its internally developed diagnostics, but buying in innovation has served Becton Dickinson well.
ESC 2018 preview – A possible boost for Abbott, and balloons go up against stents
In a quiet year for medical devices a couple of studies are still worth watching.
Medtechs prioritise efficiency when it comes to hiring
Big cap medtech is hiring, largely thanks to organic growth.
M&A comes back with a bang – or two – in medtech
The preponderance of large deals comes partly as a consequence of soaring market valuations; paradoxically, it is also a cause of them.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.